On Sept. 17, 2020, BioNTech announced an agreement with Novartis to acquire their GMP certified manufacturing facility in Marburg, Germany. The manufacturing site expanded BioNTechﾒs COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational.

The transaction was expected to close in the fourth quarter of 2020. The Company plans to be able to produce up to 250 million doses of BNT162b2 in the first half of 2021.